27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
BTIG’s Timothy Chiang maintained a Buy rating on
Buy The Weakness
Although the stock has declined 17 percent year to date, it has outperformed specialty pharma sector as a whole, which is down 34 percent. Chiang believes that this weakness offers an attractive buying opportunity.
“While “fear factors” continue to weigh on the group, including fear of earnings growth cuts due to some form of government drug price controls, we believe lawmakers may have little appetite for direct government negotiation of drug prices,” Chiang pointed out
The analyst also believes that the completion of the acquisition of the generic segment from Allergan plc Ordinary Shares (NYSE: AGN) would drive the Teva Pharmaceutical up.
Acquisition Delayed
The company has earlier announced that there would be a delay in the completion of this acquisition, from early April to June 2016. “We believe the FTC’s review is taking longer as the generic pipelines for the two companies are evaluated by the FDA for potential overlap,” Chiang mentioned.
The analyst also stated that the EU regulators had recently approved the generics deal, and that the transaction was valued at $40.5 billion. Teva will be acquiring Allergan generic segment, which generated sales worth $6,375 million in 2015.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!